TSE:4502Pharmaceuticals
Takeda (TSE:4502) Valuation After Positive Phase 3 Zasocitinib Data Boosts Dermatology Pipeline Potential
Takeda Pharmaceutical (TSE:4502) just delivered encouraging Phase 3 data for its TYK2 inhibitor zasocitinib in moderate to severe plaque psoriasis, and the market is reassessing what this pipeline asset could mean for future growth.
See our latest analysis for Takeda Pharmaceutical.
Investors seem to be warming back up to Takeda, with the latest TYK2 data arriving after a strong year to date 16.6 percent share price return and a 1 year total shareholder return of 22.7 percent. This suggests...